IL-12/23 inhibitors are monoclonal antibodies that target and block the activity of interleukin-12 and interleukin-23, cytokines involved in the inflammatory response and immune regulation. These agents are significant in clinical practice for their role in treating autoimmune conditions such as psoriasis and inflammatory bowel disease, where they help reduce inflammation and improve symptoms. An example of an IL-12/23 inhibitor is ustekinumab, which can lead to complications like increased risk of infections.
Please confirm you want to block this member.
You will no longer be able to:
Please allow a few minutes for this process to complete.